Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Net Margin (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Net Margin for 16 consecutive years, with 10.7% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 701942.0% year-over-year to 10.7%, compared with a TTM value of 21.41% through Dec 2025, up 2600229.0%, and an annual FY2025 reading of 3.63%, up 1717324.0% over the prior year.
  • Net Margin was 10.7% for Q4 2025 at Arrowhead Pharmaceuticals, up from 6.29% in the prior quarter.
  • Across five years, Net Margin topped out at 67.78% in Q1 2025 and bottomed at 7008.72% in Q4 2024.
  • Average Net Margin over 5 years is 809.91%, with a median of 165.54% recorded in 2021.
  • The sharpest move saw Net Margin crashed -374551bps in 2023, then soared 701942bps in 2025.
  • Year by year, Net Margin stood at 229.13% in 2021, then soared by 71bps to 66.82% in 2022, then crashed by -5605bps to 3812.33% in 2023, then plummeted by -84bps to 7008.72% in 2024, then surged by 100bps to 10.7% in 2025.
  • Business Quant data shows Net Margin for ARWR at 10.7% in Q4 2025, 6.29% in Q3 2025, and 643.4% in Q2 2025.